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Abstract
Group 2 innate lymphoid cells (ILC2s) are distributed systemically and produce type 2 cytokines 
in response to a variety of stimuli, including the epithelial cytokines interleukin (IL)-25, IL-33, 
and thymic stromal lymphopoietin (TSLP). Transcriptional profiling of ILC2s from different 
tissues, however, grouped ILC2s according to their tissue of origin, even in the setting of 
combined IL-25, IL-33R and TSLPR-deficiency. Single-cell profiling confirmed a tissue-
organizing transcriptome and identified ILC2 subsets expressing distinct activating receptors, 
including the major subset of skin ILC2s, which were activated preferentially by IL-18. Tissue 
ILC2 subsets were unaltered in number and expression in germ-free mice, suggesting that 
endogenous, tissue-derived signals drive the maturation of ILC2 subsets by controlling expression 
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of distinct patterns of activating receptors, thus anticipating tissue-specific perturbations occurring 
later in life.
Introduction
Group 2 innate lymphoid cells (ILC2s) are defined by their ability to produce type 2 
cytokines, in particular interleukin 5 (IL-5) and IL-13, by integrating inputs from multiple 
ligands, including cytokines, neuropeptides and eicosanoids1,2. The epithelial cytokines 
IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) are powerful ILC2 activating 
ligands, and mice deficient in these signaling pathways display substantial compromise in 
the capacity of mature lung ILC2s to generate type 2 cytokines in response to helminths and 
allergens3–7. Recent analyses of murine and human ILCs have indicated transcriptomic 
heterogeneity of ILC2s in tissues8–10; however, direct comparisons of ILC2s among normal 
resting tissues are limited and complicated by sorting strategies that rely on surface markers 
that are variably expressed by ILCs. Furthermore, functional characterization of the signals 
that establish the homeostatic activation profiles of ILC2s across and within disparate 
tissues, particularly in skin, are lacking.
In this study, we combine analysis of mouse cytokine reporter alleles with RNA sequencing 
approaches to comprehensively assess the constitutively function-marked populations of 
ILC2s present in resting bone marrow and peripheral tissues11,12. We further analyze germ-
free mice and mice triple-deficient in IL-33, IL-25 and TSLP signaling, to uncover key 
determinants of homeostatic effector cytokine function that remains intact even in the 
absence of commensal microbiota, as assessed by the ILC2-defining cytokines IL-5 and 
IL-13. Remarkably, although IL-5+ ILC2s required IL-33, IL-25 and TSLP signaling for 
optimal homeostatic type 2 cytokine competency in a tissue-dependent manner, the 
transcriptomic signatures imprinted by each tissue in which ILC2s reside dictated their 
identity. Receptiveness to independent activating signals segregated by tissue, as highlighted 
by skin ILC2s, which, like smaller ILC2 subsets in lung and bone marrow, expressed the 
IL-18R and produced type 2 cytokines in response to IL-18. In the absence of IL-18, this 
ILC2 subset was functionally impaired both in the steady-state and after inflammatory skin 
challenge. The expression of activating receptors by a tissue-specific program even in the 
absence of ligand-receptor signals reveals an anticipatory logic underpinning the roles for 
type 2 immune responses among different organs and tissues.
Results
Basal activation defines tissue-resident ILC2s
The epithelial cytokines IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) are 
important activating signals for ILC2s in homeostasis and in response to tissue injury. To 
assess the impact of combined TSLP, IL-33, and IL-25 deficiency on ILC2s under steady-
state conditions, we analyzed ILC2s from multiple tissues in 8–12-week-old YRS mice that 
express reporter alleles for arginase-1 (Yarg), IL-5 (Red5; R5), and IL-13 (Smart13; 
huCD4), which are highly expressed among resting (YR7,11,13) and activated (S14,15) ILC2s; 
cells from YRS mice triple-deficient in TLSPR, IL-33R and IL-25 (TKO-YRS7; Fig. 1a) 
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were collected and analyzed similarly (below). Among lineage-negative (Lin-) cells from 
YRS mice, we assessed R5+ ILC2s in the lung, gut (small intestine lamina propria), fat 
(perigonadal adipose tissue), and skin; the latter had diminished Yarg expression and 
variable expression of other common ILC2 surface markers. ILC2s from bone marrow 
expressed Yarg but were R5- (Fig. 1b and Supplementary Fig. 1). These findings are 
consistent with previous characterizations of these reporter alleles11,13,16. Although bone 
marrow ILC2s did not spontaneously express the R5 or S13 reporter alleles as in other 
tissues, stimulation with PMA and ionomycin resulted in robust IL-5 and IL-13 release and 
expression of cytokine reporter alleles in >90% of these cells, thereby confirming the 
identity of the Yarg+ bone marrow ILC2 population by their ability to produce hallmark 
ILC2 cytokines (Fig. 1c-e).
The widespread distribution of R5+ ILC2s in resting tissues suggested that ILC2s are 
activated by stimuli in the absence of apparent exogenous challenge. To decipher these 
signals, we performed RNA sequencing (RNA-seq) to compare the transcriptomes of 
purified R5+ ILC2s isolated from lung, gut, fat, and skin, and Yarg+ ILC2s from bone 
marrow (which are R5-). Compared to bone marrow ILC2s, peripheral tissue steady-state 
ILC2s expressed significantly increased transcripts encoding growth factors, cytokines and 
cytokine-related genes (e.g., Areg, Il2, Il5, Il13, Lif, Tnf, Tnfsf10, Cish), transcriptional 
regulators (e.g., Fos, Jun, Klf4, Klf5, Klf6, Irf4, Maff, Egr1, Egr2, Epas1, Nfkbiz), nuclear 
factors (e.g., Nr4a1, Nr4a2, Nr4a3), enzymes (e.g., Tnfaip3, Plk3, Clk4, Dusp1, Dusp4, 
Dusp5, Dusp10) and extracellular receptors associated with lymphoid cell activation (e.g., 
Cd44, Cd69, Il2rb, Ctla4, Kit, Ccr4, Ccr8) (Fig. 1f, Supplementary Fig. 2, and 
Supplementary Table 1). These results highlight the basal activation state of tissue-resident 
ILC2s, although heterogeneity is apparent among different tissues. Indeed, the 
transcriptional profile of steady-state tissue ILC2s resembled the shared transcriptional 
programs of tissue effector ILC2s and CD4+ helper T cells (TH2) cells elicited by type 2 
immune stimulation7,17.
Basal ILC2 activation is independent of microbiota
Steady-state stimulation by commensal microbes has been implicated in epigenetic and 
transcriptional alterations among intestinal ILC subsets10. With this in mind, we examined 
the tissue ILC2 activation program in germ-free mice as compared with mice housed in 
specific pathogen-free (SPF) barrier conditions. Similar numbers of ILC2s (defined in lungs, 
skin, fat, and bone marrow as Lin-CD45+Thy1.2+CD25+, or in gut as Lin-
CD45+KLRG1+IL-17Rb+, in the absence of the fluorescent reporters) were recovered from 
the lungs, skin, gut, fat, and bone marrow of germ-free and SPF mice (Fig. 2a-c, and 
Supplementary Fig. 3a, b). Additionally, steady-state eosinophil numbers, which depend 
on ILC2-derived IL-511, were not significantly different in germ-free animals as compared 
to SPF controls (Fig. 2d), indicating that although the presence or absence of particular 
commensal microbes can alter intestinal ILC subset composition10, these changes do not 
significantly impact cytokine-influenced functional outcomes of the tissue ILC2 activation 
program. In confirmation of these findings, we detected similar expression of Il5 transcripts 
in comparing germ-free and SPF ILC2s isolated from bone marrow, fat, lung, gut, and skin 
(Fig. 2e). Transcript abundance for Gata3, Arg1, and for receptor components for tissue-
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derived cytokines, such as Il1rl1 (encoding the IL-33 receptor subunit T1/ST2), Il17rb 
(encoding the IL-25 receptor subunit IL17RB), and Tnfaip3 (encoding the ubiquitin-
modifying enzyme A20 induced by NF-κB signaling) were also comparable 
(Supplementary Fig. 3c-g). Thus, tissue programs driving peripheral ILC2 activation are 
independent of commensal microbes and are likely driven by tissue-intrinsic signals.
Distinct tissue signals drive resident ILC2 activation
Tissue-derived signals, such as the cytokines IL-25, IL-33, and TSLP, control type 2 
cytokine production from ILC2s in peripheral tissues in response to infectious or 
homeostatic perturbations3,7,15,18,19, and synergize with other ILC2 activation signals such 
as leukotrienes20 and neuropeptides21. We assessed whether these three signals contributed 
to the resting activation profile of ILC2s by examining multiple tissues from triple-reporter 
YRS and TKO-YRS mice, which lack responsiveness to TLSP, IL-33, and IL-25 cytokine 
signals. Importantly, TKO-YRS mice harbored normal numbers of total ILC2s in lung, fat, 
and gut (Fig. 3a-c), although the numbers of activated IL-5-expressing R5+ ILC2s were 
significantly reduced in these peripheral tissues (Fig. 3d-f and Supplementary Fig. 4), 
extending prior observations of lung ILC2s7. Peripheral eosinophil numbers were also 
diminished in TKO-YRS mice, consistent with the role for ILC2s in sustaining systemic 
IL-5 (Fig. 3g). The magnitude of the reduction in R5+ ILC2s, however, was not consistent 
among peripheral tissues; notably, the skin contained comparable numbers of R5+ ILC2s in 
wild-type-YRS and TKO-YRS mice (Fig. 3h), indicating that signals apart from IL-25, 
IL-33, and TSLP sustain steady-state IL-5 production from skin ILC2s.
To explore this further, we compared the transcriptional profiles of ILC2s from YRS and 
TKO-YRS mice isolated from multiple tissues. In agreement with the reporter gene 
expression and in agreement with prior studies7,15,19, type 2 cytokine transcripts were 
reduced in TKO-YRS ILC2s isolated from lung, fat, and gut (Supplementary Fig. 5d, e). 
Clustering based on the top 1000 differentially expressed genes, however, revealed that the 
major transcriptional signatures from wild-type and TKO ILC2s were tissue-specific, and 
independent of the presence or absence of these epithelial cytokines (Fig. 4a and 
Supplementary Fig. 5a-e). Among wild-type R5+ or Yarg+ ILC2s, tens to hundreds of 
transcripts were differentially expressed by ILC2s collected from single tissues as compared 
to all other tissues, with gut and skin ILC2s showing the greatest numbers of divergent 
transcripts from the other groups. Notably, we observed enhanced Il17rb expression in gut 
ILC2s but significantly increased Il18r1 in skin ILC2s (Fig. 4b, Supplementary Fig. 5f, g, 
and Supplementary Table 1). Collectively, these findings suggest that distinct tissue-
derived factors contribute to ILC2 subset activation in the steady state.
Single-cell RNA sequencing distinguishes ILC2 subsets
To explore further the nature of ILC2 tissue signatures and to discern whether these 
differences identified by bulk RNA-seq resulted from contamination by non-hematopoietic 
tissue cells, we performed single-cell RNA sequencing (scRNA-seq) on 35,396 sorted ILC2s 
from bone marrow and peripheral tissues. In confirmation of the bulk sequencing results, 
scRNA-seq analysis of the aggregated ILC2s from multiple tissues showed segregation by 
tissue, which could be further sub-clustered within each tissue, revealing novel intra-tissue 
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ILC2 subsets (Fig. 5a and Supplementary Fig. 6a-c). We observed minimal (<2%; 
Supplementary Fig. 6b) contamination by non-ILC2 cells, and, in agreement with the bulk 
sequencing results, common transcripts such as Gata3, Il7r, and Crlf2 (encoding the TSLP 
receptor subunit TSLPR) were expressed by the majority of ILC2s across tissues, whereas 
other transcripts were enriched in particular tissues (Fig. 5b-f and Supplementary Figs. 6c, 
and 7), consistent with tissue-specific functional roles. The gene encoding the IL-33 
receptor subunit Il1rl1 was enriched among fat and lung ILC2s, corresponding to a loss of 
IL-5 reporter R5 expression in ILC2s from these tissues in mice lacking this receptor (Fig. 
5d and Supplementary Fig. 4). The gene encoding the IL-25R, Il17rb, was abundant among 
gut ILC2s, and matched the loss of R5 expression predominantly among small intestinal 
ILC2s in mice lacking IL-25 (Fig. 5e and Supplementary Fig. 4). These findings are 
consistent with prior studies linking IL-33 to steady-state ILC2 function in fat and lung19,22 
and IL-25 to small intestinal ILC2 function15,23. In contrast, skin ILC2s showed 
comparatively low expression of both IL-25 and IL-33 receptors, as assessed both by flow 
cytometry and transcript analysis, and consistent with unaltered IL-5 expression among 
TKO skin ILC2s (Fig. 5d, e, g, Supplementary Figs. 4, 6c and Supplementary Table 1). 
Of note, skin ILC2s expressed IL-18R1 (CD218) cell surface protein and Il18r1 transcript, 
even in germ-free mice (Supplementary Fig. 3h). In agreement with the bulk RNA-seq 
results, IL-18 receptor subunit expression was also enriched on subsets of lung and bone 
marrow ILC2s identified by scRNA-seq and flow cytometry (Fig. 5f, h and Supplementary 
Fig. 6b, c). These findings raise the possibility that IL-18 could influence ILC2 function in a 
tissue- and subset-specific manner.
IL-18 independently activates IL-18R-bearing ILC2s
IL-1 cytokine family members, including IL-18 and IL-33, can induce cytokine expression 
from lymphoid cells, particularly in the presence of STAT5 activators such as IL-7 and 
TSLP24,25. To test the function of IL-18 on these IL-18R-bearing peripheral ILC2 subsets, 
we sorted ILC2s from skin and lung and cultured them with IL-18 and TSLP in vitro. As 
compared to TSLP alone, ILC2s produced significantly higher amounts of IL-13 in the 
presence of IL-18 (Fig. 6a), and in agreement with a recent characterization of IL-18-
responsive ILCs isolated from human tissues9. Intradermal injection of IL-18 and TSLP into 
S13 reporter mice increased IL-13 reporter expression among both skin and lung ILC2s 
(Fig. 6b), indicating that IL-18R1 expression on ILC2s mediates type 2 cytokine production 
from these cells in response to IL-18. To determine whether IL-18 contributes to the steady-
state production of type 2 cytokines from ILC2s, we compared S13 and R5 reporter allele 
expression on wild-type ILC2s to those on an IL-18-deficient background (IL-18 KO). 
Although the numbers of R5+ ILC2s in wild-type and IL-18 KO mice were comparable 
(Supplementary Fig. 8a, b), S13 expression and R5 fluorescence were significantly 
reduced in IL-18-deficient skin ILC2s in comparison with wild-type control cells (Fig. 6c, 
d), revealing a non-redundant role for IL-18 as a steady-state activator of IL-18R1-
expressing ILC2s. We considered how IL-18 might contribute to steady-state activation of 
ILC2s in the presence or absence of other endogenous activating cytokines, including IL-25 
and IL-33, in light of their tissue- and subset-specific receptor expression patterns. Although 
total R5+ ILC2s were reduced in the lungs of TKO animals (Fig. 3d and Supplementary 
Fig. 4), the IL-18R1+ R5+ ILC2 subset was expanded in number when compared to wild-
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type control mice, both in the steady-state and in response to intranasal IL-18 (Fig. 6e). 
These observations indicate that IL-18 could preferentially mediate activation and type 2 
cytokine production from the IL-18R1-expressing ILC2 subset independent of IL-25, IL-33, 
and TSLP. In further support of this notion, IL-18 mediated activation and cytokine reporter 
expression among bone marrow IL-18R1+ Yarg+ ILC2s in the absence of IL-33R (ST2) 
expression, although the latter was required to respond to IL-33 (Fig. 6f). As receptor 
components for both IL-33 and IL-18 were expressed on some ILC2 subsets, we tested 
whether these two cytokines combined to control the steady-state expression of IL-5 in 
IL-18R1-expressing ILC2 subsets in skin and lung. Indeed, R5 expression among lung and 
skin ILC2 subsets bearing CD218 and/or ST2 was significantly reduced in mice that lacked 
both IL-18 and the IL-33 receptor ST2 when compared to wild-type controls (Fig. 6g). Thus, 
patterns of activating receptors have biologic significance that are organ-specific and based 
upon the subsets of ILC2s populating that tissue.
Blunted type 2 skin inflammation in the absence of IL-18
ILC2s have been shown to be increased in lesional skin of patients with atopic dermatitis 
and in mouse models of atopic dermatitis-like inflammation5,26. Our findings that IL-18 can 
activate skin ILC2s and that loss of IL-18 leads to reduced activation of skin ILC2s in 
homeostasis (Fig. 6a-d) led us to further examine whether IL-18 contributed to ILC2 
function in the context of an in vivo mouse model of skin inflammation. In order to test this, 
we used topical application of MC903, a well characterized mouse model of atopic-like 
inflammation that has been shown to activate ILC2s and cause eosinophilia, skin swelling 
and type 2 inflammation26. Compared to wild-type mice, IL-18-deficient mice exhibited 
decreased skin tissue accumulation of total ILC2s and of IL-5- and IL-13-producing ILC2s 
(Fig. 7a-c), which are critical determinants of eosinophil recruitment into tissues7. Indeed, 
mice deficient in IL-18 also showed a corresponding decrease in the numbers of eosinophils 
recruited to ear skin tissue in response to MC903 (Fig. 7d). These data suggest that IL-18 
not only influences basal ILC2 subset activation in the steady-state but also contributes to 
their function in models of atopic dermatitis.
Discussion
ILC2s are largely tissue-resident cells with a canonical effector function centered around the 
production of type 2 cytokines, particularly in response to key activating cytokines like 
IL-33, IL-25 and TSLP. Here, we show that expression of these cytokine receptors impacts 
cytokine discharge from ILC2s, but with varying effects in different tissues, reflecting 
unappreciated diversity in receptor expression on ILC2 subsets in different organs. Indeed, 
some ILC2 subsets, including most skin ILC2s, express low levels of receptors for epithelial 
cytokines IL-33, IL-25 and TSLP, and instead are activated dominantly by IL-18, which is 
highly expressed on skin ILC2s and sub-populations of ILC2s in lung and bone marrow. 
Strikingly, transcriptomic profiling of ILC2s revealed tissue-specific subsets of cells whose 
expression patterns remained largely unaffected by the absence of signaling through the 
three canonical epithelial cytokines. These tissue-specific expression patterns, including the 
capacity to respond to epithelial cytokines or IL-18, were normal in germ-free and cytokine-
deficient mice, uncovering a tissue-derived signature responsible for preemptively 
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establishing responsiveness of ILC2 subsets in different tissues in anticipatory fashion, since 
normal receptor expression and tissue distribution occur even in the absence of ligand-
mediated stimulation.
These tissue signatures reveal new potential therapeutic targets among particular cytokine 
receptor-bearing subsets of ILC2s. Notably, in IL-18-deficient mice, the IL-18R-bearing 
ILC2s in the skin exhibited a substantial defect in the homeostatic activation of ILC2s in 
vivo. Moreover, ILC2 proliferation and activation, as well as eosinophil recruitment, were 
blunted in IL-18-deficient animals after skin challenge with MC903, a well-characterized 
mouse model of atopic-like dermatitis. These results are particularly intriguing as transgenic 
mice that overexpress IL-18 in keratinocytes develop severe dermatitis27, and elevated IL-18 
correlates with disease severity in atopic dermatitis28,29, raising the possibility that targeting 
IL-18 may represent a novel means to ameliorate type 2 immune activation in the skin. In 
addition, given that receptor components for both IL-33 and IL-18 were expressed on some 
ILC2 subsets, activation by these two signals either alone or in combination may influence 
allergic diseases like asthma and atopic dermatitis. Indeed, the genes for IL-18R1 and 
IL-33R receptors are located together in the genome at an interval linked by GWAS with risk 
for allergic diseases in large cohorts30,31.
Further study using appropriate fate-mapping tools will be required to determine whether 
these tissue-specific expression profiles are acquired during fetal or perinatal development 
when ILC2s become established in tissues12,16,32, and how these programs are engaged 
during differentiation from bone marrow precursors in adults, or after tissue insults like 
helminths and allergens. Intriguingly, ILC2 effector function is expressed post-birth, and 
may create an additional layer of control along with tissue resident macrophages during this 
critical period of growth and development, where cell identity becomes established within 
temporal proximity to tissue differentiation33, and before the maturation of tissue-resident 
adaptive immunity. Importantly, our findings suggest discrete stages in the development of 
mature tissue ILC2s34. ILC2 precursors are first seeded into tissues, where they acquire a 
tissue-specific transcriptome characterized by expression of distinct subsets of activating 
receptors and an activated, poised, phenotype. The subsequent generation of the canonical 
type 2 cytokines is then regulated by the generation of distinct sets of ligands that converge 
on receptors expressed by ILC2s specific to that tissue. How and why these diverse tissue 
pathways converge on the canonical type 2 cytokines and related effectors in ILC2s 
distributed across multiple tissues continues to be an important issue that may provide 
understanding of processes firmly at the nexus of homeostasis and allergic immunity.
Accession Codes
All RNA-seq and scRNA-seq data generated in this study are deposited in Gene Expression 
Omnibus (GEO) under accession code GSE117568.
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting 
Summary linked to this article.
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Data availability
The data that support the findings of this study are available from the corresponding author 
upon reasonable request.
METHODS
Mice.
Il5Red5, Arg1Yarg, and Il13Smart reporter alleles on wild-type and triple-deficient Crlf2-/-
Il25-/-Il1rl1-/- C57BL/6J backgrounds were bred and maintained as described 
previously7,9,10,28. Il18-/- mice were obtained from The Jackson Laboratory (Stock 004130) 
and crossed with Il5Red5 and Il13Smart alleles to generate Il18-/- dual reporter mice. For all 
experiments, age-(7–14 weeks) and sex-matched mice maintained under specific pathogen-
free conditions were used. For in vivo cytokine treatments, mice were injected 
subcutaneously with rmIL-18 (2.5 μg), rmTSLP (500 ng), and/or rmIL-33 (2.5 μg) in 
calcium- and magnesium-free phosphate buffered saline (PBS) or intranasally with rmIL-18 
(500 ng), rmTSLP (100 ng) prior to analysis 18–24 h after injection. Germ-free C57BL/6J 
mice were a gift of the UCSF Gnotobiotic Core Facility. For MC903 experiments, mouse 
ears were treated with MC903 or ethanol for 5 consecutive days and as previously 
described35. All animal procedures were approved by the University of California San 
Francisco Institutional Animal Care and Use Committee.
Flow cytometry and cell sorting.
Single-cell suspensions from bone marrow (BM), lung, adipose tissue (fat), and small 
intestinal lamina propria (gut) were prepared are previously described15,18,36. For skin 
single-cell suspensions, pooled ear/back or back tissue was minced in RPMI-1640 with 10% 
FBS, then transferred to C tubes (Miltenyi Biotec), containing 5 ml of RPMI-1640 
supplemented with Collagenase XI (2 mg/ml; Sigma C9407), Hyaluronidase (0.5 mg/ml; 
Sigma H3506), and DNAse I (0.1 mg/ml; Sigma 10104159001). Samples were shaken at 
200–250 rpm for 90 min at 37 °C, then dispersed using an automated tissue dissociator 
(GentleMACS; Miltenyi Biotec) running program C. Single-cell suspensions were passed 
through a 70-μm filter and washed twice with RPMI containing 10% FBS. The following 
antibodies, all from BioLegend (unless otherwise specified) were used at 1:100 dilution 
unless noted: anti-CD3 (17A2), anti-CD4 (RM4–5), anti-CD5 (53–7.3), anti-CD8α (53–
6.7), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD19 (6D5), anti-CD25 (PC61), anti-
CD44 (IM7), anti-CD45 (30F-11, BD Biosciences), anti-CD49b (DX5; eBiosciences), anti-
CD103 (2E7), anti-CD127 (A7R34), anti-CD218 (P3TUNYA, diluted 1:200; eBiosciences), 
anti-F4/80 (BM8), anti-Gr-1 (RB6–8C5), anti-IL-17RB (9B10, diluted 1:20), anti-NK1.1 
(PK136), anti-NKp46 (29A1.4), anti-Thy1.2 (53–2.1; diluted 1:500); anti-human CD4 
(RPA-T4, diluted 1:20; eBiosciences), anti-KLRG1 (2F1; eBiosciences), anti-TSLPR 
(polyclonal; R&D Systems, diluted 1:20), anti-SiglecF (E50–244; BD Biosciences), anti-
T1/ST2 (DJ8; MD Biosciences). Live/dead cell exclusion was performed with DAPI (4′,6-
diamidine-2′-phenylindole dihydrochloride; Roche). Cell counts were performed using flow 
cytometry counting beads (CountBright Absolute; Life Technologies) per manufacturers 
instructions.
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ILC2s were sorted from reporter mice as live (DAPI-), lineage-negative (CD3, CD4, CD8, 
CD11b, CD11c, CD19, NK1.1, NKp46, Gr-1, F4/80, Ter119, DX5) CD45+Red5+ for all 
tissues except for bone marrow (Lin-CD45+Thy1.2+Yarg+) and Crlf2-/-Il25-/-Il1rl1-/- small 
intestine ILC2s (Lin-CD45+Klrg1+Yarg+) using a MoFlo XDP (Beckman Coulter). For 
germ-free mice, ILC2s were sorted as Lin-CD45+Thy1.2+CD25+. Sample data were 
acquired with a 5-laser LSRFortessa X-20 flow cytometer and BD FACSDiva software (BD 
Biosciences) and analyzed using FlowJo software (Tree Star).
RNA preparation and qRT-PCR.
ILC2s from various tissues (1,000–10,000 cells per sample) were sorted into RLT Plus lysis 
buffer (Qiagen) and stored at -80 °C, then processed using RNeasy Micro Plus kit (Qiagen) 
per manufacturer’s protocol. For qPCR analyses, RNA was reverse transcribed using 
SuperScript VILO cDNA synthesis kit (ThermoFisher) and amplified using Power SYBR 
Green PCR master mix (ThermoFisher) using primers from PrimerBank as listed in 
Supplementary Table 2.
RNA sequencing.
Total RNA was prepared as indicated above, and quality was assessed by Agilent 2100 
Bioanalyzer (Agilent Technologies). RNA-sequencing libraries were generated using the 
Illumina TruSeq stranded mRNA kit, according to the manufacturer’s protocol (Illumina). 
Library concentrations were measured using KAPA Library Quantification Kits (Kapa 
Biosystems), and equal amounts of indexed libraries were pooled and sequenced on the 
HiSeq 4000 (Illumina). Sequencing yielded ~6.5 billion reads with a mean read depth of 
97.7 million reads/sample. Reads were then aligned to the Mus musculus genome and those 
that mapped uniquely to known mRNAs were used to assess differential expression. 
Differential gene expression testing was carried out using DESeq2 (doi: 10.1186/
s13059-014-0550-8). DESeq2 was used to carry out pairwise comparisons between tissues 
with the same genotype and between genotypes in the same tissue. Additionally, DESeq2 
was run using a multifactorial model to identify the general effect of each tissue on gene 
expression (bone marrow was modeled as the intercept), the general effect of the knockout 
(wild-type as the intercept) and an interaction term between the genotype and the tissue.
For single-cell RNA sequencing (scRNA-seq), ILC2s were sorted as described above into 
ice-cold 0.5% BSA in PBS and processed through the Chromium Single Cell 3′ v2 Library 
Kit (10X Genomics) per the manufacturer’s protocol. Each channel was loaded with 5,000 
to 25,000 cells from each tissue, yielding between 400–11,600 single cells for analysis from 
each tissue. The cells were then partitioned into Gel Beads in Emulsion in the instrument, 
where cell lysis and barcoded reverse transcription of RNA occurred, followed by 
amplification, shearing, and 5′ adaptor and sample index attachment. Libraries were 
sequenced on an Illumina HiSeq 4000. Single Cell 3′ libraries used standard illumina 
sequencing primers for both sequencing and index reads and were run using paired-end 
sequencing with single indexing where Read1 is 26 cycles and Read 2 is 98 cycles.
The resulting bcl files were de-multiplexed using bcl2fastq2.1.7v and the resultant paired-
end fastq files were aligned to the mm10 transcriptome (ftp://ftp.ensembl.org/pub/
Ricardo-Gonzalez et al. Page 9
Nat Immunol. Author manuscript; available in PMC 2019 March 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
release-84/fasta/mus_musculus/dna/Mus_musculus.GRCm38.dna.primary_assembly.fa.gz, 
ftp://ftp.ensembl.org/pub/release-84/gtf/mus_musculus/Mus_musculus.GRCm38.84.gtf.gz) 
using STAR aligner which comes packaged in Cellranger toolkit (version 2.0.0) provided by 
10X Genomics. Cellranger aggr was used to aggregate multiple libraries. Details of the 
pipeline are provided in Supplementary Table 3.
In vitro cell cultures and cytokine quantification.
Sorted ILC2s were cultured at 1500–3000 cells/well (37 °C, 5% CO2) for 24 h in 100 μl of 
media containing high glucose (4.5g/L) DMEM, 10% heat-inactivated FBS, 3.7g/L 
NaHCO3, 0.036g/L L-Asparagine, 0.116g/L L-Arginine, 0.006 g/L folic acid and 
supplemented with 10 mM HEPES pH 7.4, penicillin-streptomycin, and 2-mercaptoethanol 
(Life Technologies), plus IL-7, IL-18, IL-33, and and/or TSLP (all at 10 ng/ml; R&D 
Systems), or where indicated, ionomycin (500 ng/ml) and phorbol 12-myristate 13-acetate 
(PMA; 40 ng/ml; Sigma). Cell-free supernatants were collected after centrifugation for 
protein analysis, while cell pellets were resuspended and stained for flow cytometric 
analysis. Supernatants were assayed for IL-5 and IL-13 protein amounts using Cytometric 
Bead Array Flex Sets, acquired with a 5-laser LSRFortessa X-20 flow cytometer and BD 
FACSDiva software and analyzed using Flow Cytometric Analysis Program (FCAP) Array 
software (BD Biosciences).
Statistical analysis.
Results from independent experiments were pooled whenever possible, and all data were 
analyzed using Prism 7 (GraphPad Software) by comparison of means using unpaired two-
tailed Student’s t tests. Statistical analysis for RNA-seq data is described above. Data in all 
figures represent mean ± s.d. unless otherwise indicated.
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Figure 1: Steady-state ILC2 activation in multiple peripheral tissues.
a, ILC2s were analyzed in multiple tissues from wild-type (WT) or Crlf2–/–IL25–/–Il1rl1–/– 
triple-deficient (TKO) mice on Arg1 (Yarg); R5 (IL-5); S13 (IL-13) combined triple-reporter 
(YRS) background. b, Representative flow cytometry of CD45+Lin- cells from indicated 
WT-YRS mouse tissues. c, d, Representative flow cytometry (c) and percentage (d) of sorted 
Yarg+ bone marrow (BM) ILC2 expressing R5 and S13 reporter alleles before and after 
stimulation with ionomycin (Ion) and phorbol 12-myristate 13-acetate (PMA). e, IL-5 and 
IL-13 in supernatants of Yarg+ ILC2 sorted from WT-YRS BM or lung tissue cultured in 
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IL-7 or Ion/PMA for 24 h. f, RNA-seq analysis of select transcripts significantly enriched 
(FDR<0.01) in R5+ ILC2s from peripheral tissues (lung, gut, fat, skin) versus Yarg+ BM 
ILC2s. b, c, Data representative of 3 independent experiments and in (d-f) represent 
biological replicates (n=3; mean±SD). f, Data represent mean normalized read counts 
(fragments per million mapped reads) from biological replicates (n=3, BM; n=5, lung; n=6, 
fat, gut, skin).
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Figure 2: ILC2 distribution and homeostatic function is independent of the microbiota.
a, b, Number of ILC2s (Lin-CD45+Thy1.2+CD25+) in lungs (a), and skin (b). c, c, 
Percentage of gut ILC2s (Lin-CD45+IL17rb+KLRG1+) out of total CD45+ cells. d,Number 
of spleen eosinophils in C57BL/6 mice housed in specific pathogen-free (SPF) or germ-free 
(GF) conditions. e, Quantitative RT-PCR (qPCR) analysis of Il5 transcript abundance among 
ILC2s sorted from SPF or GF mouse tissues. a-d, Data pooled from 2 or more independent 
experiments with n≥4 from each tissue and expressed as mean±SD. e, Data represent 
biological replicates (n=3; mean⩲SD) and are normalized to Rps17.
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Figure 3: Tissue-resident ILC2s depend on distinct tissue signals.
a-b, Number of ILC2s (Lin-CD45+Thy1.2+CD25+) in lungs (a) and fat (b). c, percentage of 
ILC2s (Lin-CD45+KLRG1+) out of total CD45+ cells in gut among wild-type (WT) or 
Crlf2–/–IL25–/–Il1rl1–/– triple-deficient (TKO) mice on Arg1 (Yarg); R5 (IL-5); S13 (IL-13) 
triple-reporter (YRS) backgrounds. d-f, Number of R5+ ILC2s (Lin-CD45+) in lungs (d), fat 
(e), and gut (f) tissues of WT-YRS and TKO-YRS mice. g, Numbers of eosinophils in 
spleen. h, Number of R5+ ILC2s in skin (Lin-CD45+) of WT-YRS and TKO-YRS mice. 
Data pooled from 2 or more independent experiments with n≥10 mice per group, represented 
as mean⩲SD; **, p<0.001; ***, p<0.0001.
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Figure 4: Transcriptional heterogeneity of tissue-resident ILC2s.
a, t-distributed stochastic neighbor embedding (tSNE) plot representing ILC2 samples. 
ILC2s were sorted from lung, fat, gut, skin (Lin-CD45+Red5+), and bone marrow (BM, Lin-
CD45+Yarg+) as outlined in the gating strategy shown in Supplementary Figure 1. b, 
RNA-seq analysis of differentially expressed transcripts (FDR<0.01) among ILC2s from 
each tissue versus all other tissues; select upregulated transcripts in each tissue highlighted. 
Data pooled from 3 independent experiments with n≥3 biological replicates per group.
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Figure 5: Tissue map of ILC2 signals revealed by single-cell RNA sequencing.
a, tSNE plot representing 35,396 ILC2s sorted from BM (Lin-CD45+Yarg+), lung, fat, gut 
and skin (Lin-CD45+Red5+) analyzed by single-cell RNA sequencing (scRNA-seq). b-f, 
normalized relative expression of Gata3 (b), Il7r (c), Il1rl1 (d), Il17rb (e), and Il18r1 (f) 
transcripts. g-h, Representative flow cytometric staining for T1/ST2 (IL-33R), IL17Rb 
(IL-25R) (g), and CD218 (IL-18R1) (h) among ILC2s from indicated WT-YRS mouse 
tissues. g, h, Data are representative of 3 independent experiments. h, numbers represent the 
percentage of ILC2s positive for CD218 (right of dotted line).
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Figure 6: IL-18 independently mediates ILC2 subset activation.
a, IL-13 in supernatants of ILC2s (Lin-CD45+Thy1.2+Red5+) sorted from skin or lung tissue 
and cultured in TSLP alone or TSLP and IL-18. b, Percentage of skin and lung ILC2s (Lin-
CD45+Thy1.2+Red5+) expressing S13 reporter allele after intradermal injection of PBS or 
TSLP and IL-18. c, d, Percentage of skin ILC2s expressing S13 reporter allele (c) and R5 
reporter median fluorescence intensity (MFI) (d) among skin ILC2s from WT and IL18-
deficient (KO) mice on a R5; S13 dual-reporter background. e, Number of IL-18R1+R5+ 
ILC2s in lungs of WT-YRS and TKO-YRS mice 24 h after intranasal administration of PBS 
or recombinant IL-18. f, Percentage of IL-18R1+Yarg+ ILC2s sorted from BM of WT or 
ST2 KO mice expressing S13 reporter allele 24 h after culture in IL-7+IL-33 or IL-7+IL-18. 
g, Representative flow cytometry of R5 reporter expression among skin and lung ILC2s 
(Lin-CD45+Thy1.2+) from WT and IL-18–/–ST2–/–deficient (DKO) mice on a R5; S13 dual-
reporter background. Numbers indicate percent R5 positive in each quadrant. Data in (a-f) 
pooled from 2 or more independent experiments for a total of at least 3 mice per group, 
represented as mean⩲SD; *, p<0.01; **, p<0.001; ***, p<0.0001.
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Figure 7: Blunted type 2 skin inflammation in the absence of IL-18.
a-d, Total skin ILC2s (Lin-CD45+Thy1.2+CD25+) (a), R5+ ILC2s (Lin-
CD45+Thy1.2+Red5+) (b), percentage of R5+ ILC2s expressing S13 reporter allele (c), and 
total eosinophils (d) in ears of wild type or IL-18KO mice treated with ethanol (EtOH) or 
MC903. Data pooled from 2–3 individual experiments with n≥6 for each experimental group 
and are represented as mean±SEM; *, p<0.05; **(p<0.005); ***, p<0.0005, ****, 
p<0.00005.
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